Prostate Cancer

New research on the downstream outcomes following PSA screening may help inform individualized decisions among older men considering screening.

Intermittent androgen deprivation therapy (ADT) may compromise survival for metastatic hormone-sensitive prostate cancer patients compared with continuous ADT, according to a recently published multicenter study.

More than half of prostate cancers detected by PSA measurement are intermediate or high risk at diagnosis, according to findings from a large, population-based study.

The American College of Physicians has become the latest organization to weigh in on the controversial subject of PSA screening for prostate cancer.

Eighteen years of follow-up of the Prostate Cancer Prevention Trial (PCPT) suggests that 7 years of treatment with the 5-alpha-reductase inhibitor finasteride (Proscar) for prostate cancer prevention does not appear to affect mortality but does reduce the risk of a prostate cancer diagnosis.

Older men with metastatic castration-resistant prostate cancer (CRPC) derive a similar if not superior survival benefit from treatment with enzalutamide (Xtandi) as do younger men, according to a post-hoc analysis of the phase III AFFIRM trial.

Increased adoption of the practice of obtaining 10- to 12-core biopsy specimens of the prostate has resulted in increased detection of prostate cancer across the United States, a recent large study shows.

Baldness was associated with an increased risk of prostate cancer among African-American men, and risk for advanced prostate cancer increased with younger age and type of baldness, reported researchers from the University of Pennsylvania, Philadelphia.

Researchers at the University of Maryland have identified a peptide derived from Pacific cod that may inhibit prostate cancer and possibly other cancers from spreading.

Since the days of the digitally directed prostate nodule biopsy using the Vim-Silverman needle, the optimum prostate biopsy strategy has evolved.

The American Society for Radiation Oncology’s board of directors recently approved a statement regarding the use of proton beam therapy for prostate cancer, presumably due to recent reports suggesting the treatment provides little long-term benefit over traditional radiation despite its higher cost.

Anticoagulation while on docetaxel (Taxotere) chemotherapy appears to be an independent predictor of survival in men with metastatic castration-resistant prostate cancer (mCRPC).

Focal laser ablation is safe and can be performed without the troubling complications associated with more aggressive therapies for low-risk prostate cancer, results of a small phase I study indicate.

More stringent criteria may be needed for African-American men with prostate cancer when considering active surveillance for their disease, new research from The Cancer Institute of New Jersey, New Brunswick suggests.

Patients with high-risk prostate cancer who undergo 18 months of androgen blockade live as long as those who have 36 months of treatment, according to results of a recent phase III study.

Nearly three-quarters of patients undergoing radiation therapy for prostate cancer had no evidence of the disease at 25 years’ follow-up, the authors of a study from Radiotherapy Clinics of Georgia, Atlanta recently reported.

The AUA has released a new white paper providing recommendations for optimal prostate biopsy sampling, labeling, and processing.

The incidence of secondary malignancies following prostate cancer therapy is similarly uncommon whether the treatment is surgery, brachytherapy, or external beam therapy.

Advanced age does not influence postoperative continence or cancer-specific survival after radical prostatectomy, according to a recent study.

Urologists share how confident they feel about active surveillance for low-risk prostate cancer.

A new study suggests that exercise may reduce Caucasian men's risk of developing prostate cancer.

Many synthetic chemicals, untested for their disrupting effects on the hormone system, may have significant health implications, including contributing to the development of prostate cancer in men and undescended testes in young males.

Three "field effect" epigenetic biomarkers were found to be more prevalent in histologically benign biopsy cores from prostate cancer patients diagnosed with Gleason score 7 prostate cancer than in those with low-volume Gleason 6 disease, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.

A large study presented at the Genitourinary Cancers Symposium in Orlando, FL has confirmed that prostate cancer detection rates are enhanced when 10 to 12 specimens are obtained during biopsy.

Patients with high-risk prostate cancer who received 18 months of hormone therapy lived as long as patients treated for 36 months, Canadian researchers report.